BRACCO'S ACQUISITION OF SQUIBB DIAGNOSTICS
This article was originally published in The Gray Sheet
Executive Summary
BRACCO'S ACQUISITION OF SQUIBB DIAGNOSTICS creates a U.S. company with a broad diagnostic imaging agents pipeline, including contrast agents for x-ray, magnetic resonance imaging, and ultrasound, as well as radiopharmaceuticals. In addition to its core imaging products already on the market -- the x-ray imaging agent Isovue (iopamidol) and MRI contrast agent ProHance (gadoteridol) -- the Bristol-Myers Squibb subsidiary has at least three products in its pipeline.
You may also be interested in...
Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition
Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.